An observational study in Metastatic Prostate Carcinoma, Stage IIIB Prostate Cancer AJCC v8 and Stage IIIC Prostate Cancer AJCC v8, sponsored by Thomas Jefferson University. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Thomas Jefferson University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Prostatic Neoplasms by Thomas Jefferson University — 4 open to participants now, 7 under way, 2 of them phase 3. Prostatic Neoplasms · Thomas Jefferson University.
Among the 14 studies in Prostatic Neoplasms by Thomas Jefferson University, this one is one of 2 that started in 2024, is one of 3 observational ones, and was the 9th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →4 of the 14 studies in Prostatic Neoplasms by Thomas Jefferson University are open now, in 1 country. Recruiting first, the newest first:
Thomas Jefferson University · Sites in United States
Ages 18+ · Men only
Thomas Jefferson University · Sites in United States
Ages 18+ · Men only
Thomas Jefferson University
Ages 18+
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 55 across the 11 interventional studies, 118 across the 3 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
Thomas Jefferson University is the lead sponsor of 394 studies on the registry; 69 are open to participants now.
Of its 45 completed or terminated interventional studies of FDA-regulated products, 21 (47%) have results posted.
3 of the studies in Prostatic Neoplasms by Thomas Jefferson University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06024772Phase 3Thomas Jefferson UniversityMultiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer | 2027-08-01 |
| NCT05627219Thomas Jefferson UniversityExtending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network | 2027-07 |
| NCT05487846Thomas Jefferson UniversityPeer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Prostatic Neoplasms by Thomas Jefferson University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial evaluates whether a network of peer genetic coaches is useful for addressing disparities in genetic testing and screening among African American men with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). While genetic testing has become central to prostate cancer care, African American men are less likely seek testing due to lack of awareness, cultural beliefs, financial limitations, fear of discrimination, and mistrust in the healthcare system. A network of peer genetic coaches may help address barriers, beliefs, and needs of African American men in the community and provide navigation to increase engagement in genetic testing.
PRIMARY OBJECTIVES:
I. Identify and train 6 African American (AA) men as peer genetic coaches (PGCs) for the Extending Prostate Genetic Awareness, Navigation, and Delivery (EXPAND) Network. (Train peer genetic coaches) II. Conduct a feasibility study of peer genetic coaching. (Provide individual coaching)
SECONDARY OBJECTIVE:
I. Patient-related outcomes will include change in decisional conflict for genetic counseling, acceptability/attitude toward genetic counseling and testing, and change of genetics knowledge.
OUTLINE:
AIM 1: Peer genetic coaches undergo training and education on study.
AIM 2: Patients receive an educational booklet and attend a discussion with a peer genetic coach on study.
Men who have experience with both prostate cancer (PCA) and genetic counseling and testing, as well as peer education or navigation experience. African American men with a history of prostate cancer or with a strong family history of prostate cancer, breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer, uterine cancer, renal cancer, urothelial cancer, or upper bowel cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AIM 1: Peer genetic coaches undergo training and education on study. AIM 2: Patients receive an educational booklet and attend a discussion with a peer genetic coach on study.
Behavioral: Training and Education · Other: Educational Intervention · Procedure: Discussion
Undergo training and education
Receive educational booklet
Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational
Attend discussion with peer genetic coach
Also known as: Discuss
Number of inquiries to the central number (feasibility)
Time frame: Up to 1 year
Percent of callers screened and eligible to participate (feasibility)
Time frame: Up to 1 year
Percent of eligible callers who enroll in the study (feasibility)
Time frame: Up to 1 year
Percent who complete the endpoint assessment (feasibility)
Time frame: Up to 1 year
Number and percent of men making genetic counseling appointments
Time frame: Up to 1 year
Change in decisional conflict for genetic counseling
Reported with mean and standard deviation.
Time frame: Baseline up to 1 year
Change in acceptability/attitude toward genetic counseling and testing
Reported with mean and standard deviation.
Time frame: Baseline up to 1 year
Change of genetics knowledge
Reported with mean and standard deviation
Time frame: Baseline up to 1 year
Started Jun 2024 (actual). Primary completion is estimated for Jul 2027, 37 months after the start.
Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 37 months is below that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Sep 2026 → Jul 2027 and completion Sep 2026 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.